CClinicalTrials.gg
Status unknownNCT04583683ARGOSUpdated May 25, 2021

Effects of Very Low Calorie Diet vs Metabolic Surgery on Weight Loss and Obesity Comorbidities

An interventional study of Very low calorie diet with Fortimel (Nutricia) supplementation and Metabolic Surgery in Obesity, Morbid, Obesity and Diet, Healthy, sponsored by Catholic University of the Sacred Heart. Status unknown at 1 site in Italy. Open to participants aged 19 Years to 69 Years. Per ClinicalTrials.gov, last updated 2021-05-25.

Sponsored by Catholic University of the Sacred Heart · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2021), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
19 Years to 69 Years
Sex
All
01

Study summary

It is a prospective randomized trial on 218 subjects, 109 for each arms. The purpose of this trial is to compare very low calorie diet and metabolic surgery induced weight loss and its maintenance.

Read the detailed description

Obesity is a leading public health issued associated with poor quality of life, morbidity and an increased mortality rate. Although metabolic surgery results in a greater weight loss when compared to non-surgical approaches, a low calorie diet associated with intensive maintenance session may be a valid alternative for weight loss. Since lifestyle interventions are safer and potentially more cost effective than metabolic surgery, this trial will test whether an intensive lifestyle intervention is as effective as metabolic surgery to induce weight loss and its maintenance.

A total of 218 participants will be randomly assigned to metabolic surgery (109) or intensive lifestyle intervention (109).

Clinical outcomes will be assessed at 25% reduction in Body Mass Index (BMI), at 12 months and 24 months.

02

Conditions studied

  • Obesity, Morbid
  • Obesity
  • Diet, Healthy
  • Bariatric Surgery Candidate
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's enrollment of 218 is above the median of 78 across 4,878 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Catholic University of the Sacred Heart is the lead sponsor of 227 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged between 19 and 69 years
  • Body Mass Index ≥35 kg/m2 and at least one or more obesity-related co-morbidities such as type II diabetes (T2DM), hypertension, sleep apnea and other respiratory disorders, non-alcoholic fatty liver disease, osteoarthritis, lipid abnormalities, gastrointestinal disorders, or heart disease
  • Body Mass Index ≥40 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Active cancer
  • End stage renal failure
  • End stage liver failure
  • Being unable to understand and sign informed consent
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
218 participants (actual)

Study arms

  • Active comparator
    Intensive lifestyle modification: Very low calorie diet

    Patients will undergo a very low calorie diet

    Behavioral: Very low calorie diet with Fortimel (Nutricia) supplementation

  • Active comparator
    Metabolic Surgery

    Patients will undergo metabolic surgery

    Procedure: Metabolic Surgery

Interventions

  • BehavioralVery low calorie diet with Fortimel (Nutricia) supplementation

    Patients will undergo a very low calorie diet

  • ProcedureMetabolic Surgery

    Patients will undergo metabolic surgery

06

What researchers measure

Primary outcomes

  1. Time to achieve a 25% reduction in Body Mass Index

    Time frame: 1-12 months

Secondary outcomes

  1. Percentage of participants who achieve 25% reduction in Body Mass Index

    Time frame: 1-12 months

  2. Time to achieve 25% reduction in Body Mass Index

    Time frame: 1-24months

  3. Change in body composition (lean mass-all tissues in the body except bone and fat-fat mass, bone density and visceral fat) using dual energy X-ray absorptiometry (DXA), from baseline, at 25% weight loss, at 12 months follow up and at 24 months follow up

    Time frame: 1-24months

  4. Change in glycated hemoglobin (HbA1c), from baseline, at 12 and 24 months follow up (patients with diabetes)

    Time frame: 1-24months

  5. Change in fasting glucose and fasting insulin, from baseline, at 12 and 24 months follow up

    Time frame: 1-24months

  6. Change in insulin resistance (assessed by HOMA-IR), from baseline, at 12 and 24 months follow up

    Time frame: 1-24months

  7. Change in blood pressure, from baseline, at 12 and 24 months follow up

    Time frame: 1-24months

  8. Change in total, HDL, LDL and total cholesterol from baseline, at 12 and 24 months follow up

    Time frame: 1-24months

  9. Change in triglycerides from baseline, at 12 and 24 months follow up

    Time frame: 1-24months

  10. Percentage of participants who maintain weight loss at 24 months follow up

    Time frame: 1-24months

07

Study locations

1 site
  • Catholic University School of Medicine
    Rome, 00168, Italy
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04583683
Lead sponsor
Catholic University of the Sacred Heart
Responsible party
Geltrude Mingrone (Professor, Catholic University of the Sacred Heart) — Principal investigator
First posted
Oct 12, 2020
Start date
Sep 30, 2020
Primary completion
Dec 28, 2020
Completion
Sep 30, 2022 (estimated)
Last update
May 25, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion